StockWatch: PacBio Faces Uphill Climb as Q1 Revenue Falls Short
PacBio shares plummeted 51% on Tuesday, after it reversed its earlier “guidance” forecast to investors for 5% operating expense growth this year, revealing instead plans to cut its annual operating expense run rate by $50 million to $75 million.